Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/36031
Title: | Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons. | Authors: | Adelstein S.;Nguyen M.;Corte T.J.;Jee A.S.;Sahhar J. ;Youssef P.;Bleasel J. | Institution: | (Jee, Youssef, Bleasel, Adelstein, Nguyen, Corte) Department of Respiratory, Royal Prince Alfred Hospital, Sydney, Australia (Jee, Adelstein, Corte) Sydney Medical School, University of Sydney, Australia (Sahhar) Department of Rheumatology, Monash Health, Clayton, VIC 3168, Australia (Youssef, Bleasel) Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Australia (Adelstein, Nguyen) Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia (Adelstein, Nguyen) Immunopathology Laboratory, Southwest Sydney Pathology Service, Sydney, NSW 2050, Australia | Issue Date: | 17-Sep-2019 | Copyright year: | 2019 | Publisher: | Elsevier Inc. (E-mail: usjcs@elsevier.com) | Place of publication: | United States | Publication information: | Pharmacology and Therapeutics. 202 (pp 40-52), 2019. Date of Publication: October 2019. | Journal: | Pharmacology and Therapeutics | Abstract: | Disease behaviour in interstitial lung disease (ILD) is highly variable and accurate clinical tools to predict prognosis and guide management decisions remain unsatisfactorily elusive. Accurate disease stratification would allow clinicians to better distinguish patients at risk of rapid progression requiring urgent treatment, from those indolent disease where potentially toxic drug therapy could be minimised or avoided. Several serum biomarkers have demonstrated potential utility for diagnosis and prognosis of ILD in small retrospective studies, and the hope is future multicentre prospective trials focussed on the markers with most potential will see translation to clinical practice. Two important and contrasting fibrotic lung diseases with high mortality are idiopathic pulmonary fibrosis (IPF) and systemic sclerosis associated ILD (SSc-ILD). In this era where anti-fibrotics for IPF have proven benefit, there are increasing biologic and non-biologic options for the treatment of connective tissue disease ILD (CTD-ILD), and the incidence of both is increasing, there is an urgent need to improve the diagnostic and prognostic accuracy in these complex patients. This comprehensive literature review will summarise and discuss the current evidence for the major candidate serum biomarkers in IPF and SSc-ILD. Biomarkers will be categorised by the following major mechanistic pathways (1) alveolar epithelial cell damage; (2) aberrant fibrogenesis, fibroproliferation and matrix remodelling; (3) immune dysregulation; and (4) vascular and endothelial damage. The aim is to review the rationale, potential and limitations of current candidate biomarkers and their utility in IPF and SSc-ILD to help direct future research and translation to clinical practice.Copyright © 2019 | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.pharmthera.2019.05.014 | PubMed URL: | 31153954 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31153954] | ISSN: | 0163-7258 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/36031 | Type: | Review | Subjects: | ADAMTS protein/ec [Endogenous Compound] advanced glycation end product receptor/ec [Endogenous Compound] autoantibody/ec [Endogenous Compound] B cell activating factor/ec [Endogenous Compound] *biological marker/ec [Endogenous Compound] C-C motif chemokine 18/ec [Endogenous Compound] carbohydrate antigen/ec [Endogenous Compound] chitinase 3 like protein 1/ec [Endogenous Compound] Clara cell protein/ec [Endogenous Compound] CXCL13 chemokine/ec [Endogenous Compound] endothelial leukocyte adhesion molecule 1/ec [Endogenous Compound] fibulin/ec [Endogenous Compound] heat shock protein 47/ec [Endogenous Compound] heat shock protein 70/ec [Endogenous Compound] intercellular adhesion molecule 1/ec [Endogenous Compound] interleukin 6/ec [Endogenous Compound] interleukin 8/ec [Endogenous Compound] matrix metalloproteinase/ec [Endogenous Compound] monocyte chemotactic protein 1/ec [Endogenous Compound] osteopontin/ec [Endogenous Compound] protein lysine 6 oxidase/ec [Endogenous Compound] somatomedin binding protein/ec [Endogenous Compound] transcription factor RUNX2/ec [Endogenous Compound] vascular cell adhesion molecule 1/ec [Endogenous Compound] vasculotropin/ec [Endogenous Compound] c x c chemokine motif chemokine ligand 4/ec [Endogenous Compound] carbohydrate antigen 15.3/ec [Endogenous Compound] fibulin 1/ec [Endogenous Compound] lysyl oxidase like 2/ec [Endogenous Compound] unclassified drug adaptive immunity B lymphocyte cell damage disease exacerbation fibrogenesis *fibrosing alveolitis human immune dysregulation inflammation *interstitial lung disease lung alveolus epithelium cell oxidative stress pathophysiology priority journal review *systemic sclerosis T lymphocyte subpopulation treatment response ADAM protein/ec [Endogenous Compound] lung alveolus epithelium cell oxidative stress pathophysiology priority journal Review *systemic sclerosis T lymphocyte subpopulation adaptive immunity treatment response B lymphocyte cell damage disease exacerbation fibrogenesis *fibrosing alveolitis human immune dysregulation *interstitial lung disease inflammation |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.